Skip to main content

Table 1 Overview of the current literature on mRNA-encoded antibodies

From: mRNA as novel technology for passive immunotherapy

Publication Pardi et al., 2017
[267]
Stadler et al., 2017
[264]
Thran et al., 2017
[268]
Sabnis et al., 2018
[269]
Capping (structure) Enzymatic (Cap1) Enzymatic (Cap1) Co-transcriptional (Cap0); Enzymatic (Cap1) Not disclosed (Cap1)
5′ UTR Tobacco etch virus Tobacco etch virus Hydroxysteroid (17-β) dehydrogenase 4 Unknown origin
3′ UTR Not disclosed F-I (not yet characterized) Human albumin Human alpha globin
Polyadenylation (structure) Vector-encoded (monopartite; approximately A100) Vector-encoded (bipartite; A30-linker-A70) Enzymatic adenylation (bipartite; A64-linker-PolyA) Poly(A) tail (details not disclosed)
Base modifications N1-methyl-pseudouridine N1-methyl-pseudouridine Unmodified N1-methyl-pseudouridine
Codon usage Not disclosed Sequence provided GC enrichment (disclosed in [218]) Not disclosed
mRNA purification FPLC HPLC HPLC Not disclosed
Formulation/delivery LNP/intravenous TransIT/intravenous LNP/intravenous LNP/intravenous
Dose (range) 1–1.4 mg/kg Approx. 0.25 mg/kga 0.06–2 mg/kg 0.3 mg/kg
Species M. musculus M. musculus M. musculus M. fascicularis
Maximum titer across experiments (range) 70–200 µg/ml 7 µg/ml 20–400 µg/ml 4 µg/ml
  1. aDue to lack of information, the value was calculated here for mice of 20 g in weight